Canada markets closed

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.2200-0.0500 (-2.20%)
At close: 03:58PM EST
2.1800 -0.04 (-1.80%)
After hours: 04:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.2700
Open2.3079
Bid2.2200 x 800
Ask2.2600 x 900
Day's Range2.1800 - 2.3079
52 Week Range1.7600 - 2.7000
Volume40,016
Avg. Volume39,709
Market Cap31.99M
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    James Flynn Joins ARCA biopharma Board of Directors

    WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium

  • GlobeNewswire

    ARCA biopharma Announces Third Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retaine

  • GlobeNewswire

    ARCA biopharma Announces Second Quarter 2022 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. Dr. Michael Bristow, ARCA’s Pr